The decision to recommend adjuvant chemotherapy for stage II colon cancer patients with poor prognostic factors should be made on a case-by-case basis, considering the potential benefits and risks of treatment, as well as the MSI status of the cancer. The potential benefit of adjuvant chemotherapy in stage II should be weighed against its toxicity and risk-benefit ratio.